These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 15305339)
1. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Carlsson B; Tötterman TH; Essand M Prostate; 2004 Oct; 61(2):161-70. PubMed ID: 15305339 [TBL] [Abstract][Full Text] [Related]
2. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494 [TBL] [Abstract][Full Text] [Related]
3. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Kobayashi H; Nagato T; Oikawa K; Sato K; Kimura S; Aoki N; Omiya R; Tateno M; Celis E Clin Cancer Res; 2005 May; 11(10):3869-78. PubMed ID: 15897588 [TBL] [Abstract][Full Text] [Related]
4. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648 [TBL] [Abstract][Full Text] [Related]
5. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178 [TBL] [Abstract][Full Text] [Related]
6. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Kiessling A; Füssel S; Schmitz M; Stevanovic S; Meye A; Weigle B; Klenk U; Wirth MP; Rieber EP Prostate; 2003 Sep; 56(4):270-9. PubMed ID: 12858355 [TBL] [Abstract][Full Text] [Related]
7. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247 [TBL] [Abstract][Full Text] [Related]
8. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Kim S; Lee JB; Lee GK; Chang J Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351 [TBL] [Abstract][Full Text] [Related]
10. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353 [TBL] [Abstract][Full Text] [Related]
11. Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy. Carlsson B; Forsberg O; Bengtsson M; Tötterman TH; Essand M Prostate; 2007 Mar; 67(4):389-95. PubMed ID: 17219382 [TBL] [Abstract][Full Text] [Related]
12. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632 [TBL] [Abstract][Full Text] [Related]
13. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007 [TBL] [Abstract][Full Text] [Related]
14. T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin. Wolfgang CD; Essand M; Lee B; Pastan I Cancer Res; 2001 Nov; 61(22):8122-6. PubMed ID: 11719440 [TBL] [Abstract][Full Text] [Related]
15. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers. Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376 [TBL] [Abstract][Full Text] [Related]
16. Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells. Gervais A; Bouet-Toussaint F; Toutirais O; De La Pintiere CT; Genetet N; Catros-Quemener V Anticancer Res; 2005; 25(3B):2177-85. PubMed ID: 16158961 [TBL] [Abstract][Full Text] [Related]
17. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. Elkord E; Williams PE; Kynaston H; Rowbottom AW Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246 [TBL] [Abstract][Full Text] [Related]
18. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043 [TBL] [Abstract][Full Text] [Related]
19. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols. Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]